Intellia jumps as FDA lifts hold on gene‑editing trial for rare nerve disease

Shares of gene therapy developer Intellia Therapeutics NTLA.O rise 21% to $16.87 premarket

Co says U.S. FDA has lifted clinical hold on its late‑stage trial testing nex‑z for hereditary ATTR amyloidosis with polyneuropathy — a disease caused by harmful protein deposits that damage nerves

FDA paused the study in October after a related‑trial patient had serious liver issues; Co agrees to tighter liver‑function monitoring - NTLA

Co says it will raise trial size to about 60 patients from 50 and restart enrollment quickly

Nex‑z is a one‑time therapy that co is developing with drugmaker Regeneron REGN.O, per co

Shares down ~23% in 2025